These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 37769639)

  • 1. Primary Chemoablation for Intermediate-Risk Low-Grade Bladder Cancer: New Paradigm or Added Uncertainty? Letter.
    Prasad SM
    J Urol; 2023 Dec; 210(6):840. PubMed ID: 37769639
    [No Abstract]   [Full Text] [Related]  

  • 2. Primary Chemoablation for Intermediate-risk Low-grade Bladder Cancer: New Paradigm or Added Uncertainty?
    Murthy PB; Sexton WJ
    J Urol; 2023 Nov; 210(5):726-727. PubMed ID: 37757487
    [No Abstract]   [Full Text] [Related]  

  • 3. A Systematic Review and Meta-analysis of Chemoablation for Non-muscle-invasive Bladder Cancer.
    Yanagisawa T; Quhal F; Kawada T; Mostafaei H; Motlagh RS; Laukhtina E; Rajwa P; Deimling MV; Bianchi A; Pallauf M; Majdoub M; Pradere B; Moschini M; Karakiewicz PI; Teoh JY; Miki J; Kimura T; Shariat SF
    Eur Urol Focus; 2023 May; 9(3):463-479. PubMed ID: 36517409
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Primary Chemoablation of Low-Grade Intermediate-Risk Nonmuscle-Invasive Bladder Cancer Using UGN-102, a Mitomycin-Containing Reverse Thermal Gel (Optima II): A Phase 2b, Open-Label, Single-Arm Trial.
    Chevli KK; Shore ND; Trainer A; Smith AB; Saltzstein D; Ehrlich Y; Raman JD; Friedman B; D'Anna R; Morris D; Hu B; Tyson M; Sankin A; Kates M; Linehan J; Scherr D; Kester S; Verni M; Chamie K; Karsh L; Cinman A; Meads A; Lahiri S; Malinowski M; Gabai N; Raju S; Schoenberg M; Seltzer E; Huang WC
    J Urol; 2022 Jan; 207(1):61-69. PubMed ID: 34433303
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CALIBER: a phase II randomized feasibility trial of chemoablation with mitomycin-C vs surgical management in low-risk non-muscle-invasive bladder cancer.
    Montorsi F; Moschini M; Necchi A
    BJU Int; 2020 Dec; 126(6):663. PubMed ID: 32805758
    [No Abstract]   [Full Text] [Related]  

  • 6. Chemoablation with Intensive Intravesical Mitomycin C Treatment: A New Approach for Non-muscle-invasive Bladder Cancer.
    Racioppi M; Di Gianfrancesco L; Ragonese M; Palermo G; Sacco E; Bassi P
    Eur Urol Oncol; 2019 Sep; 2(5):576-583. PubMed ID: 31411974
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chemoablation in Urothelial Carcinoma: A Systematic Review and Future Perspectives.
    Alsyouf M; Pierorazio P; Groegler J; Hu B
    Urology; 2020 Oct; 144():28-37. PubMed ID: 32540302
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The DaBlaCa-13 Study: Short-term, Intensive Chemoresection Versus Standard Adjuvant Intravesical Instillations in Non-muscle-invasive Bladder Cancer-A Randomised Controlled Trial.
    Lindgren MS; Bue P; Azawi N; Blichert-Refsgaard L; Sundelin MO; Dyrskjøt L; Jensen JB
    Eur Urol; 2020 Dec; 78(6):856-862. PubMed ID: 32736928
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk of post-operative intravesical mitomycin C instillation following transurethral bladder tumor resection.
    Shapiro O; Jones K; Wang C; Landas S; Haas GP
    Can J Urol; 2006 Dec; 13(6):3317-20. PubMed ID: 17187694
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Re: Chemoablation with Intensive Intravesical Mitomycin C Treatment: A New Approach for Non-Muscle-Invasive Bladder Cancer.
    Chang SS
    J Urol; 2020 Nov; 204(5):1095. PubMed ID: 32821005
    [No Abstract]   [Full Text] [Related]  

  • 11. Electromotive instillation of mitomycin immediately before transurethral resection for patients with primary urothelial non-muscle invasive bladder cancer: a randomised controlled trial.
    Di Stasi SM; Valenti M; Verri C; Liberati E; Giurioli A; Leprini G; Masedu F; Ricci AR; Micali F; Vespasiani G
    Lancet Oncol; 2011 Sep; 12(9):871-9. PubMed ID: 21831711
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bladder perforation: a potential risk of early endovesical chemotherapy with mitomycin C.
    Racioppi M; Porreca A; Foschi N; Delicato G; Destito A; D'Addessi A
    Urol Int; 2005; 75(4):373-5. PubMed ID: 16327311
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Comparison of the effectiveness between long-term instillation of mitomycin C and short-term prophylaxis with MMC or bacille Calmette-Guérin. Study of patients with non-muscle-invasive urothelial cancer of the urinary bladder].
    Isbarn H; Budäus L; Pichlmeier U; Conrad S; Huland H; Friedrich MG
    Urologe A; 2008 May; 47(5):608-15. PubMed ID: 18317718
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Blood and tissue levels of mitomycin C after intravesical instillation].
    Flüchter SH; Hlobil H; Harzmann R; Rothe KF; Bichler KH
    Urol Int; 1983; 38(6):321-8. PubMed ID: 6419427
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Perivesical inflammation and necrosis due to mitomycin C instillation after transurethral resection of bladder tumor: we must be vigilant!
    Fazlioglu A; Tandogdu Z; Kurtulus FO; Parlakkilic O; Cek M
    Urol Int; 2009; 83(3):362-3. PubMed ID: 19829042
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Investigation about the penetration depth in the normal bladder wall and tumor by local instillation of mitomycin into the urinary bladder.
    Aeikens B; Niermann R; Schindler E
    Urol Int; 1982; 37(6):389-93. PubMed ID: 7181985
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Durability of Response to Primary Chemoablation of Low-Grade Upper Tract Urothelial Carcinoma Using UGN-101, a Mitomycin-Containing Reverse Thermal Gel: OLYMPUS Trial Final Report.
    Matin SF; Pierorazio PM; Kleinmann N; Gore JL; Shabsigh A; Hu B; Chamie K; Godoy G; Hubosky SG; Rivera M; O'Donnell M; Quek M; Raman JD; Knoedler JJ; Scherr D; Weight C; Weizer A; Woods M; Kaimakliotis H; Smith AB; Linehan J; Coleman J; Humphreys MR; Pak R; Lifshitz D; Verni M; Klein I; Konorty M; Strauss-Ayali D; Hakim G; Seltzer E; Schoenberg M; Lerner SP
    J Urol; 2022 Apr; 207(4):779-788. PubMed ID: 34915741
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bladder wall calcification after intravesical mitomycin C treatment of superficial bladder cancer.
    Drago PC; Badalament RA; Lucas J; Drago JR
    J Urol; 1989 Oct; 142(4):1071-2. PubMed ID: 2507794
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Combination chemotherapy of mitomycin C and cytosine arabinoside in the intravesical treatment for superficial bladder tumors: report 2. Evaluation of prophylactic intravesical infusion therapy].
    Ikeuchi T; Onodera Y; Kai Y
    Gan To Kagaku Ryoho; 1984 Apr; 11(4):858-63. PubMed ID: 6426397
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Significance of urothelial dysplasia in macroscopically normal mucosa in patients with bladder tumors. Results of a randomized study with and without intravesical mitomycin C in the prevention of recurrence].
    Maier U; Holzner JH
    Onkologie; 1985 Aug; 8(4):232-40. PubMed ID: 3937968
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.